by Elena Iemma | May 17, 2023 | News
PROVIDENCE, RI, May 17, 2023 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is celebrating its 25th birthday by renewing the company’s commitment to improving human health everywhere while highlighting the development of groundbreaking tools by the company. In addition,...
by Adam | Dec 29, 2020 | News
PROVIDENCE, R.I., Dec. 29, 2020 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) today provides an update on the advancement of the company’s peptide therapeutic immunogenicity assessment program. The PANDA (Peptide Abbreviated New Drug...
by Adam | Nov 6, 2019 | News
Providence, November 6th 2019 EpiVax announces Publication of Antigen-Specific Tolerance Induction by Tregitope in Nature Scientific Reports EpiVax, Inc (“EpiVax”), a pioneer in immunoinformatics innovation, announces the publication of “Therapeutic administration of...
by Adam | Oct 5, 2018 | News
This original article was published on October 2nd, 2018 in ConvergenceRI. PROVIDENCE, RI – The U.S. Food and Drug Administration announced on Tuesday, Oct. 2, that the federal agency has awarded EpiVax and CUBRC a $1 million contract over two years to establish best...
